Kornimate/medical-research-clean huggingface dataset:
very small embryonic-like stem cells for knee osteoarthritis

Conditions: Stem Cell Transplant Complications; Knee Osteoarthritis

Summary: the aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(vsels) to knee osteoarthritis.

vsels come from the patient's peripheral blood, and will be injected in the most painful knee, or the worse knee on physical examination. then follow-up the knee pain and imaging changes at 6 months and 1 year after treatment.

Eligibility criteria:
inclusion criteria: * patients had moderate to severe osteoarthritis of both knees. * those had mechanical pain of knee joints, which was aggravated by walking or stair climbing. * those complained of gelling pain of knee joint. * those have crepitus and limitation of the joint range of motion with joint bony hypertrophy on physical examination, x-rays showed narrowing of joint space and osteophyte formation exclusion criteria: * diabetic foot and patients with obvious edema in the legs caused by various causes * blood disease patients, thrombocytopenia or dysfunction, hypofibrinemia or anticoagulant therapy, long-term use of aspirin
peach questionnaire study

Conditions: Deafness

Summary: there are few or no questionnaires in french on the hearing quality of life of children with hearing aids. the objectives of the study are to measure the hearing quality of life of children with hearing aid and / or cochlear implants and to compare the hearing quality of life according to the type of hearing aid (hearing aid and / or cochlear implant).

there are few or no questionnaires in french on the hearing quality of life of children with hearing aids. the study will allow an evaluation of the quality of life benefit of hearing rehabilitation at different ages and with varying levels of deafness. the translated questionnaire for the study will be given to the parents of the child after a sure diagnosis of the child's degree of deafness and at least 1 month of hearing aids. the translated is proposed by necker hospital pediatric ent department. the objectives of the study are to measure the hearing quality of life of children with hearing aid and / or cochlear implants and to compare the hearing quality of life according to the type of hearing aid (hearing aid and / or cochlear implant).

Eligibility criteria:
inclusion criteria: * minors aged 2 to 10 years (inclusive) * patients followed in consultation at necker hospital in the pediatric ent department * with a slight to deep bilateral deafness * auditory experience with hearing aid and / or cochlear implant bilateral for more than 1 month * holders of parental authority not opposed to participation in the study exclusion criteria: * non-wearing of hearing aid and / or implant over the last month * malfunction of hearing aids and / or implant * non-understanding of the french language by parents

Keywords: deafness in children the parents' evaluation of aural/oral performance of children (peach) in french
rosuvastatin in treating women with cardiovascular complications who are undergoing chemotherapy for breast cancer

Conditions: Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

Summary: this randomized pilot clinical trial studies rosuvastatin in treating women with cardiovascular complications who are undergoing chemotherapy for breast cancer. rosuvastatin may prevent or lessen cardiovascular complications in patients undergoing chemotherapy for breast cancer

objectives: i. evaluate the feasibility of administering rosuvastatin to breast cancer patients undergoing treatment with anthracyclines, paclitaxel, cyclophosphamide, and trastuzumab for breast cancer. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients receive rosuvastatin orally (po) once daily for 3 months in the absence of disease progression or unacceptable toxicity. arm ii: patients receive placebo po once daily for 3 months in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: women receiving therapy for breast cancer without a history of cardiovascular disease an low-density lipoprotein (ldl) cholesterol level of less than 160 mg per deciliter (3.4 mmol per liter) willingness to participate for the duration of the trial (3 months) written informed consent triglyceride level of less than 500 mg per deciliter (5.6 mmol per liter) exclusion criteria: previous or current use of lipid-lowering therapy current use of postmenopausal hormone-replacement therapy evidence of hepatic dysfunction (an alanine aminotransferase level that was more than twice the upper limit of the normal range) creatine kinase level that was more than three times the upper limit of the normal range creatinine level that was higher than 2.0 mg per deciliter (176.8 umol per liter) diabetes uncontrolled hypertension (systolic blood pressure \> 190 mm hg or diastolic blood pressure \> 100 mm hg) uncontrolled hypothyroidism (a thyroid-stimulating hormone level that was more than 1.5 times the upper limit of the normal range) recent history of alcohol or drug abuse or another medical condition that might compromise safety or the successful completion of the study exclude patients with inflammatory conditions such as severe arthritis, lupus, or inflammatory bowel disease, and patients taking immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids pregnant women are excluded from participation in this study
treatment of cutaneous leishmaniasis with a combination of miltefosine and antimony

Conditions: Cutaneous Leishmaniasis

Summary: cutaneous leishmaniasis is endemic in the new world and, until recently, the standard treatment was pentavalent antimony. the cure rate for l panamensis in colombia is 91%-93% and the cure rate in bolivia is also 90%. nevertheless, pentavalent antimonials have the disadvantages of multiple injections and mild-moderate clinical toxicity all of which are particularly unpleasant for a moderate clinical problem such as cutaneous leishmaniasis. the oral agent miltefosine has now been shown to be as effective as antimony in colombia and bolivia (91 and 92% respectively). side effects seen in patients with cutaneous disease that can be specifically attributed to the drug are nausea and vomiting of mild grade in approximately 25% of patients, and low-grade elevation of creatinine also in approximately 25% of patients. a further disadvantage of miltefosine is that regimens shorter than 4 weeks have not been evaluated for cutaneous disease. combination therapy is now being used for many infectious diseases, such as tuberculosis, malaria, and hiv. combination therapy offers the potential of preventing drug resistance, because organisms resistant to one of the drugs may be susceptible to the other drug; and also the potential to diminish drug therapy duration and thus side effects. these two potential benefits to some extent contradict each other: preventing resistance is best done if full courses of both drugs is used; diminishing therapy duration means using less than the full course of each drug. the optimum combination regimen is one in which sufficient amounts of both drugs are used to have high efficacy, yet the amounts are as low as possible to spare patients unnecessarily long courses of drug. in the present protocol, the combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. the combination of miltefosine and antimony is chosen because these are now the two standard agents in bolivia, and in vitro the combination was additive to mildly synergistic against a standard leishmania strain.


Eligibility criteria:
inclusion criteria: * parasitological confirmation * at least 1 lesion must be ulcerative * no specific antileishmanial therapy during the previous six months exclusion criteria: * concomitant diseases such as tuberculosis, hiv, diabetes, renal failure, liver disease * abnormalities ctc 2 in blood, liver, kidney test or ekg

Keywords: leishmaniasis miltefosine antimony therapy
comparison of cardiac index and stroke-volume-index measured by pulmonary artery catheter, flotrac® and argos® in cardiac surgery patients.

Conditions: Cardiac Failure Acute; Hemodynamic Monitoring

Summary: a comparison of cardiac performance determined by stroke-volume-index measured by different mechanisms in patients during and after cardiac surgery: 1. pulmonary artery catheter 2. flo trac 3. argos monitor investigations will be done in theater and on icu in ventilated and spontaneously breathing patients.


Eligibility criteria:
inclusion criteria: * patient after cardiac surgery with pulmonary artery catheter exclusion criteria: * hemodynamic instability, no consent
prevalence of obstructive sleep apnoea (osa) among 4-8 years old children in the general population

Conditions: Obstructive Sleep Apnea (OSA)

Summary: the purpose of this study is to estimated prevalence of obstructive sleep apnea (osa) in 4-8 year old children. to date, most studies estimating prevalence of sleep apnea in young children are based on utilizing subjective questionnaires. the few studies that have utilized objective sleep measures have tested only those children suspected of sleep apnea based on subjective questionnaires, finding prevalence in the range of 1-13%. untreated osa is associated with significant morbidities in children, affecting their behavior, cognitive development, cardiovascular-and cardio metabolic health, endocrine and immune function. better understanding of prevalence of sleep apnea in young children should be beneficial. this study will help to understand the prevalence of sleep apnea in each age-group of children 4-8 years of age and whether certain groups, such as children with obesity or asthma have higher prevalence and/or more severe disease. the primary objective of this study is to get better understanding of prevalence and severity of sleep apnea in young children using objective sleep measures for all participants.

the study is a population-based, observational study of 4-8 year old children located in akureyri, iceland. all parents in this geographical area will be invited for their child/children to participate in the study. parents of all participating children will be asked to answer questionnaires to assess general health, sleep habits, behavior and quality of life and then measure their sleep for five consecutive nights with a home based sleep test.

Eligibility criteria:
inclusion criteria: * children 4-8-years old exclusion criteria: * children with atrial fibrillation or ventricular trigemini
efficacy and safety of betamethasone microsphere in patients with macular edema following branch retinal vein occlusion (hikari)

Conditions: Macular Edema Following Branch Retinal Vein Occlusion

Summary: this study will evaluate the efficacy and safety of betamethasone microsphere (de-102) for macular edema following branch retinal vein occlusion


Eligibility criteria:
inclusion criteria: * 20 years of age or older * diagnosis of macular edema following branch retinal vein occlusion exclusion criteria: * bcva etdrs letter score in non-study eye \< 35 * known steroid-responder
the efficacy and safety of etanercept （yi sai pu) in chinese patients with moderate-to-severe psoriasis

Conditions: Psoriasis; Etanercept

Summary: this is a prospective, open-label, one-arm study. the study aims to assess the efficacy and safety of etanercept therapy which help guide the clinical practice in real-world settings.


Eligibility criteria:
inclusion criteria: 1.18 to 75 years of age 2.moderate to severe chronic psoriasis, bsa≥3% 3.duration of psoriasis≥6 months 4.patients must be candidate for systemic therapy or phototherapy 5.no contradiction to etanercept 6.informed consent must be obtained 7.for female, ß-hcg test is negative and contraception is accepted exclusion criteria: 1. diagnosis of pustular psoriasis, erythroderma psoriasis or drug-induced psoriasis 2. having severe infections, including hepatitis, hiv and tuberculosis 3. no live vaccines 12 weeks before enrollment, through the study and 1 year after the last dose of etanercept 4. having significant allergies to biological agents 5. having the previous experience of biologics 6. having a history of malignancy 7. having contradictions to etanercept 8. refusal of contraception 9. having serious or unstable/uncontrolled illnesses
efficacy of head-point acupuncture on insomnia

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the investigators will conduct a single-center case series study. a total of 40 participants with insomnia will be enrolled. the aim of the study is to assess the therapeutic effect of head-point acupuncture for the treatment of insomnia.

the investigators will conduct a single-center case series study. a total of 40 participants with insomnia will be enrolled, and will undergo gv20, ex-hn-1, gv21, gv22, gv23, gv24, gv29, and bilateral gb13 acupuncture treatment for 4 weeks. the primary outcomes of therapeutic effect on insomnia are changes of the pittsburgh sleep quality index (psqi), epworth sleepiness scale (ess), and the hospital anxiety and depression scale (hads).the time frame of the three primary outcomes are: baseline week 0, week 2, week 4 and week 6. the secondary outcomes of therapeutic effect on insomnia are sleep parameters including sleep efficiency (se), sleep awakenings (sa) and total sleep time (tst) recorded by the actigraphy (time frame: baseline week 0, week 2, week 4 and week 6), as well as the heart rate viability(hrv) recorded by the ecg monitor (time frame: baseline week 0, week1, week 2, week 3, week 4 and week 6; and 30 minutes before and 60 minutes after acupuncture through study completion).

Eligibility criteria:
inclusion criteria: 1. aged 20\~80 years, 2. met the diagnostic criteria of insomnia according to the diagnostic and statistical manual of mental disorders (fifth edition, dsm-v) 3. experienced insomnia at least three times a week for more than a month 4. voluntarily agreed with the investigation and signed a written informed con- sent form before the clinical trial started. exclusion criteria: 1. a pregnant or lactating woman 2. the patient's insomnia is caused by mental disorders other than mild anxiety, 3. the patient has serious cardiovascular, liver, kidney or hematopoietic system disease 4. the patient's insomnia is caused by nervous system disease (eg, stroke, parkinson's disease) 5. the patient has taken chinese herbs and herbal formulas for insomnia two weeks before the trial 6. the patient with cardiac pacemaker 7. the patient does not want to wear portable physiological signal recording device (somnowatchtm) and handheld ecg monitor 8. the patient has a history of sleep apnea

Keywords: acupuncture primary insomnia
a study of regn7544 for the treatment in adult patients with sepsis-induced hypotension

Conditions: Sepsis-Induced Hypotension

Summary: this study is researching an experimental drug called regn7544 (called "study drug"). the study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. the aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during your stay in the hospital. the study is looking at several other research questions, including: * how the study drug changes the blood pressure and the amount of intravenous (iv) fluids given to participants with low blood pressure due to sepsis * what side effects may happen from taking the study drug * how much study drug is in the blood at different times * whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)


Eligibility criteria:
key inclusion criteria: 1. proven or suspected infection defined as administration or planned administration of antibiotics within the screening period 2. sepsis-induced hypotension that has not responded to intravenous (iv) fluids, receiving 1 or 2 vasopressors and maintaining a mean arterial pressure (map) of ≥ 65 mm hg for at least 2 consecutive hours immediately prior to randomization, as defined in the protocol key exclusion criteria: 1. unable to obtain informed consent by participant or legally authorized representative (lar) 2. clinical status requires vasopressor and/or blood pressure (bp) management inconsistent with the study protocol 3. receiving continuous neuromuscular blockade during the screening period 4. primary cause of hypotension suspected to be due to non-sepsis cause (eg, hemorrhage, burns, or cardiogenic shock), including shock after cardiac arrest 5. ejection fraction \<20% in the most recent known echocardiogram 6. acute coronary syndrome based on clinical symptoms and/or electrocardiogram (ecg) during hospitalization 7. history of hospitalization due to heart failure, myocardial infarction, stroke, clinically significant ventricular arrhythmia, transient ischemic attack, or unstable angina within the preceding 3 months 8. any prior diagnosis of severe pulmonary hypertension, as defined in the protocol 9. receiving 3 or more vasopressors or exceeding the maximal combined dose as defined in the protocol, during the screening period or at the time of study drug administration 10. chronic mechanical ventilation for any reason or severe chronic obstructive pulmonary disease (copd) requiring either continuous daily oxygen use or mechanical ventilation (for acute exacerbation of copd) prior to hospital admission 11. received bone marrow transplant during the preceding 6 months or chemotherapy during the preceding 30 days for lymphoma or leukemia note: other protocol-defined inclusion-exclusion criteria apply

Keywords: natriuretic peptide receptor 1 (npr1) low blood pressure
clinico-demographic profile of the patient with pancreaticobiliary malignancy undergoing ercp in a tertiary care center of nepal

Conditions: Cholangiocarcinoma; Bile Duct Carcinoma; Endoscopic Retrograde Cholangio-Pancreatography; Pancreatic Neoplasms

Summary: background pancreaticobiliary malignancy (pbm) is a group of cancers affecting pancreas and bile duct. the diagnosis is often late and with fatal outcomes. here, investigators study the clinicodemographic profile of the patients with suspected pbm undergoing endoscopic retrograde cholangiopancreatography (ercp) at a tertiary care center in nepal. material and methods retrospectively, a descriptive cross-sectional study was conducted at the endoscopy unit of the internal medicine department of dhulikhel hospital-kathmandu university hospital (dh-kuh) from jan 2017 to jan 2023. patients over 18 years of age with suspected pbm with complete medical records who underwent ercp were included in our study. the descriptive and correlation statistics were done.


Eligibility criteria:
inclusion criteria: * above 18years of age. * those with confirmed pancreaticobiliary malignancies, diagnosed through histopathology from ercp, or endoscopic ultrasound (eus), or computerized tomography (ct) guided biopsy, and who underwent ercp * those with strong suspicions of malignancy confirmed by clinical, ct scan and ercp findings, and who also underwent ercp exclusion criteria: * those with suspected intrahepatic cholangiocarcinoma, who underwent percutaneous transhepatic cholangiography with biliary drainage * those with incomplete hospital records

Keywords: bile duct cholangiocarcinoma endoscopic retrograde cholangiopancreatography nepal pancreatic neoplasm
evaluation of the effects of chinese medical treatment on leucopenia after chemotherapy in breast cancer patients

Conditions: Leucopenia; Breast Cancer

Summary: this is a two-year double blind, placebo-controlled, and randomized clinical trial, which is aimed to evaluate the effects of chinese medical treatment on leucopenia after chemotherapy in breast cancer patients.

the study will be conducted in the department of breast surgery in china medical university hospital, taichung. one hundred newly diagnosed breast cancer patient (age ≧18, stage i, ii, iiia) will be included. after the diagnosis, the patients will undergo operation. then, each patient will receive one of the following protocol of chemotherapy according to her pathology report and overall evaluation: "fec\*6", "fec\*4+taxotere\*4", and "fec\*3+taxotere\*3". every participator will start to take the powder of chinese herb-lch1 after her receiving first time of chemotherapy until she receives the next cycle.(while receiving "fec", it will be 3 weeks. while receiving "taxotere", it will be 4 weeks). just before receiving the next cycle of chemotherapy, the blood of the participator will be sampled to check her cbc, got/gpt, bun/cr and tumor maker. the investigators also adopt the body constitution questionnaire (bcq) to evaluate the chinese medical constitutional status, the eortc qlq-c30, eortc qlq-br23, and karnofsky score to evaluate the quality of life, and to evaluate the adverse effects of the adjuvant chemotherapy with the nci-ctcae version 3.0. each participator will take the powder of chinese herb-lch1 from her first chemotherapy till 3 weeks after the last cycle of chemotherapy. over all, it will take about 18 weeks (fec\*6) to 28 weeks (fec\*4+taxotere\*4) to complete the treatment. this study will also investigate the influence of the chemotherapy on the chinese medical constitutional status, and in order to provide the basis for the complementary treatment for the breast cancer by adjusting and balancing the constitutional status of the patients.

Eligibility criteria:
inclusion criteria: * newly diagnosed breast cancer patient (age ≧18, stage i, ii, iiia) * receive chemotherapy after operation exclusion criteria: * before receiving operation and chemotherapy, the patient already have other chronic diseases. * already have hematological malignancy and other lethal disease. * pregnant. * have severe psychological diseases.

Keywords: patients receiving chemotherapy
antibiotics versus surgery in acute appendicitis

Conditions: Acute Appendicitis Without Peritonitis

Summary: the acute appendicitis (aa) is a very common disease with a life time risk 7-8% and the highest incidence in the second decades . the aetiology of aa is still poor understood: the commonest hypothesis refers to appendix obstruction followed by impairment of wall appendix barrier and thus wall perforation and/or abscess formation1. however some studies suggest that no-complicate and complicate appendicitis are different entities allowing a different treatment. the study aims to test the no inferiority in terms of efficacy of antibiotic treatment compared to surgery in a population with high probability to suffer of 1st episode of aa.the study aims to test the no inferiority in terms of efficacy of antibiotic treatment compared to surgery in a population with high probability to suffer of 1st episode of aa.


Eligibility criteria:
inclusion criteria: * patients between 18 and 65 years old * first episode of suspected aa diagnosed by andersson's score or combination with abdominal ultrasound exclusion criteria: * patients with any potential immunodeficiency status * assumption of antibiotics for different infectious disease or surgery in the last 30 days * allergy to antibiotics established in the study protocol * no acceptance of study protocol * pregnancy or delivery in the last 6 months * asa iv or v, no italian or english fluently speakers.

Keywords: acute appendicitis surgery antibiotics comparison surgery and antibiotics resolutions of symptoms